Crohn S Disease Articles & Analysis
10 news found
No identifiable prior medical treatment; Impossibility for the patient to participate in prolonged medical follow-up; Unstable psychotic disorders, severe depressive syndromes that have not been stabilized with a specific treatment, suicidal tendencies; Alcoholism or drug addiction; Severe eating disorders (such as bulimia); An insufficient mastication coefficient; Documented ...
An equally effective oral alternative could change the treatment paradigm for a number of patient populations, including those with autoimmune diseases, cancer, and diabetes. “Therapeutic drug development has yielded a vast array of molecular entities, including peptides, antibodies and oligonucleotides. ...
Inflammatory bowel disease (IBD), mainly divided into Crohn's disease (CD) and ulcerative colitis (UC), are diseases whose causes are not fully understood and for which there is no cure. The chronic progression of IBD is characterized by periods of symptomatic relapses and symptom-free phases. During relapses, acute inflammation occurs in the bowel of IBD patients, leading to typical symptoms ...
Founded in 2007, SetPoint is dedicated to developing technologies to treat patients with chronic autoimmune diseases. The company is pioneering a new treatment paradigm, using electrical pulses that activate the body’s innate “inflammatory reflex,” for rheumatoid arthritis (RA), Crohn’s ...
Results further support the benign safety profile of VE202 and identify an optimal dosing regimen Vedanta plans to initiate a Phase 2 clinical trial of VE202 in ulcerative colitis patients in the second half of 2021 Vedanta Biosciences, a leading clinical-stage microbiome company developing a new category of oral therapies using defined bacterial consortia manufactured from clonal cell ...
TEL AVIV, Israel, May 19, 2021 /PRNewswire/ -- CytoReason, an Israeli company developing a computational model of the human body for faster drug discovery and development, today announced a collaboration with Swiss multinational biopharmaceutical company, Ferring Pharmaceuticals, which aims to establish new treatment options for patients with inflammatory bowel disease (IBD). This is the first ...
” Study recruitment is now open for enrollment. Following the trial’s completion, SFA expects to finalize the SFA002 formulation and proceed into a randomized controlled clinical trial. ...
G-Tech Medical’s Lindsay Axelrod presented her abstract with preliminary findings from an ongoing collaborative study with Stanford University supported by the Helmsley Charitable Trust. The study involves using non-invasive wireless electrode patches to read myoelectrical signals from the gut over 3 days in patients with Crohn’s ...
PRLog - SFA Therapeutics, Inc. announced today that FDA has granted an official Orphan Drug Designation (ODD) to SFA001, the company's novel human-microbiome-based treatment for human hepatocellular carcinoma (HCC). "By granting an Orphan Drug Designation to SFA001, FDA has given a special status to treatment of the most prevalent form of liver cancer. This ODD designation will provide SFA ...
A few years ago, researchers discovered that the gut bacterium Faecalibacterium prausnitzii was present at lower levels in individuals affected by inflammatory bowel diseases (IBDs), such as Crohn’s disease or ulcerative colitis.They also found that this species secretes one or more molecules with anti-inflammatory ...